Veteran in the fight against SARS Since the outbreak of the epidemic, as a veteran in the fight against SARS, Prof. Jiang Shanping, Director of the Department of Respiratory Medicine of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, has been closely following the development of the epidemic, and was the first to put forward the treatment plan of “chloroquine phosphate for new coronavirus pneumonia”, and participated in promoting relevant scientific research and clinical studies, contributing to the wisdom and strength of experts in the fight against the epidemic. He was the first to propose the treatment plan of “Chloroquine phosphate for the treatment of new coronavirus pneumonia”, and participated in the promotion of related scientific research and clinical studies, contributing the wisdom and strength of the experts of Sun Yat-sen University to the anti-epidemic work. On January 19, assigned by Academician Song Erwei, President of Sun Yat-sen Memorial Hospital and Professor Wang Jingfeng, Secretary of the Party Committee of Sun Yat-sen University, Professor Jiang Shanping participated in the meeting on prevention and treatment of new coronavirus pneumonia organized by the Scientific Research Group of the New Coronavirus Pneumonia Prevention and Control Command and Control Office of Guangdong Province, according to the resolution of the meeting, Professor Jiang Shanping took the lead in undertaking one of the important contents of the Guangdong Province’s Emergency Special Project for the Prevention and Control of the New Coronavirus Science and Technology Research –Research on the role of low molecular heparin in protecting vascular endothelial cells and preventing pulmonary microvascular embolism in improving the prognosis of severe pneumonia with new coronavirus, and the research results have been applied to the rescue and treatment programs for severe patients with new coronavirus pneumonia, with very good results. On January 27, Prof. Jiang Shanping participated in a meeting on the prevention and treatment of neocoronavirus pneumonia, including Academician Xu Tao from the Provincial Laboratory of Regenerative Medicine and Health, Guangzhou, Chinese Academy of Sciences, with whom he discussed the possibility of chloroquine phosphate in the treatment of neocoronavirus pneumonia in depth and formulated a scientific research program. After the formulation of the program, Prof. Jiang Shanping, together with the designated hospital, the Fifth Affiliated Hospital of Sun Yat-sen University, implemented and carried out the clinical research of chloroquine phosphate for the treatment of new coronavirus pneumonia under the premise of ensuring the life safety of patients. On February 7, Guangdong Provincial Department of Science and Technology, Guangdong Provincial Health Commission jointly organized by academician Zhong Nanshan, with the participation of relevant experts from more than 10 hospitals in the province, jointly developed a multi-center collaborative plan and formed an expert consensus on chloroquine phosphate treatment of new coronavirus pneumonia. According to the collaborative program and expert consensus, more than 10 sentinel hospitals in the province carried out the clinical trial study of chloroquine phosphate for the treatment of new coronavirus pneumonia. The Fifth Affiliated Hospital of Sun Yat-sen University is the project leader, and President Shan Hong is the general director of the project. The dosage of chloroquine phosphate has been adjusted As of March 4, 2020, the cumulative enrollment of chloroquine phosphate for the treatment of new coronavirus pneumonia patients is 120 cases, of which 9 cases of light type, accounting for 7.50%; 107 cases of ordinary type, accounting for 89.1%; and 4 cases of heavy type, accounting for 3.33 %. Currently there are 110 patients whose nucleic acid test of pharyngeal swab has turned negative after taking the drug. Among the negative cases, there are 9 cases of light type, accounting for 100% (9/9); 97 cases of general type, accounting for 90.65% (97/107); 4 cases of severe type, accounting for 100% (4/4); the average number of days to turn negative after taking the drug is 4.4 days. None of the 120 patients treated with chloroquine phosphate developed into the critical type, and 81 cases have been discharged from the hospital. No serious adverse reactions have been found in the course of drug administration. The scientific research and clinical practice of chloroquine phosphate has been highly affirmed by the Ministry of Science and Technology of the People’s Republic of China (MOST), the Health Commission of the People’s Republic of China (HICC) and a high-level panel of experts. On February 19, the National Health Commission of the People’s Republic of China (NHRC) and the Bureau of Traditional Chinese Medicine (BCM) issued the “New Type of Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Sixth Edition)”, in which chloroquine phosphate was included. On February 24, Prof. Jiang Shanping reported the latest clinical research experimental results to the National Health Commission, proposing adjustments to improve the clinical rescue effect. on February 27, the National Health Commission, the Administration of Traditional Chinese Medicine and other ministries and commissions issued the Notice on Adjustment of Trial Dosage of Chloroquine Phosphate for the Treatment of New Coronavirus Pneumonia to further provide scientific guidance on the dosage and use of Chloroquine Phosphate. Source: Guangzhou Daily